KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Net Income towards Common Stockholders fell 4476.19% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 5005.01%. This contributed to the annual value of -$234.3 million for FY2024, which is 2847.53% down from last year.
  • Xenon Pharmaceuticals' Net Income towards Common Stockholders amounted to -$90.9 million in Q3 2025, which was down 4476.19% from -$84.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$15.1 million in Q3 2021 and a low of -$90.9 million during Q3 2025
  • Over the past 5 years, Xenon Pharmaceuticals' median Net Income towards Common Stockholders value was -$44.7 million (recorded in 2023), while the average stood at -$46.0 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Net Income towards Common Stockholders tumbled by 1259882.35% in 2021, and later tumbled by 1486.81% in 2024.
  • Xenon Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$25.1 million in 2021, then plummeted by 49.05% to -$37.4 million in 2022, then fell by 19.7% to -$44.7 million in 2023, then crashed by 77.77% to -$79.5 million in 2024, then fell by 14.28% to -$90.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$90.9 million for Q3 2025, versus -$84.7 million for Q2 2025 and -$65.0 million for Q1 2025.